Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Exelixis Reigns In Spending, It Looks To Offload Early-Stage Assets

This article was originally published in The Pink Sheet Daily

Executive Summary

Management elaborates on plans to scale down early discovery and drug development to focus resources on its three lead partnered drugs.
Advertisement

Related Content

Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results
Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results
Exelixis Stays The Course Under New Leadership of Michael Morrissey
Exelixis Stays The Course Under New Leadership of Michael Morrissey
Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out
Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out
Exelixis Reorganizes R&D And Cuts Its Workforce By 40 Percent
Exelixis Reorganizes R&D And Cuts Its Workforce By 40 Percent
Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors

Topics

Advertisement
UsernamePublicRestriction

Register

PS070459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel